» Articles » PMID: 29888232

Sulforaphane Augments Glutathione and Influences Brain Metabolites in Human Subjects: A Clinical Pilot Study

Overview
Specialty Psychiatry
Date 2018 Jun 12
PMID 29888232
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Schizophrenia and other neuropsychiatric disorders await mechanism-associated interventions. Excess oxidative stress is increasingly appreciated to participate in the pathophysiology of brain disorders, and decreases in the major antioxidant, glutathione (GSH), have been reported in multiple studies. Technical cautions regarding the estimation of oxidative stress-related changes in the brain via imaging techniques have led investigators to explore peripheral GSH as a possible pathological signature of oxidative stress-associated brain changes. In a preclinical model of GSH deficiency, we found a correlation between whole brain and peripheral GSH levels. We found that the naturally occurring isothiocyanate sulforaphane increased blood GSH levels in healthy human subjects following 7 days of daily oral administration. In parallel, we explored the potential influence of sulforaphane on brain GSH levels in the anterior cingulate cortex, hippocampus, and thalamus via 7-T magnetic resonance spectroscopy. A significant positive correlation between blood and thalamic GSH post- and pre-sulforaphane treatment ratios was observed, in addition to a consistent increase in brain GSH levels in response to treatment. This clinical pilot study suggests the value of exploring relationships between peripheral GSH and clinical/neuropsychological measures, as well as the influences sulforaphane has on functional measures that are altered in neuropsychiatric disorders.

Citing Articles

Endogenous extraction yielded high quality sulforaphane from broccoli sprouts unveils potent antioxidant and anti-Alzheimer's activities.

Uthaman S, Kang W, Park J, Kim S, Le D, Oh S Heliyon. 2025; 11(4):e42673.

PMID: 40034321 PMC: 11875816. DOI: 10.1016/j.heliyon.2025.e42673.


Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration.

Bernstein H, Nussbaumer M, Vasilevska V, Dobrowolny H, Nickl-Jockschat T, Guest P Mol Psychiatry. 2024; 30(3):1102-1116.

PMID: 39639174 PMC: 11835740. DOI: 10.1038/s41380-024-02861-6.


The role of isothiocyanate-rich plants and supplements in neuropsychiatric disorders: a review and update.

Ramakrishnan M, Fahey J, Zimmerman A, Zhou X, Panjwani A Front Nutr. 2024; 11:1448130.

PMID: 39421616 PMC: 11484503. DOI: 10.3389/fnut.2024.1448130.


Oxidative stress and food as medicine.

Carlson D, True C, Wilson C Front Nutr. 2024; 11:1394632.

PMID: 39262430 PMC: 11387802. DOI: 10.3389/fnut.2024.1394632.


Sulforaphane Effects on Cognition and Symptoms in First and Early Episode Schizophrenia: A Randomized Double-Blind Trial.

Hei G, Smith R, Li R, Ou J, Song X, Zheng Y Schizophr Bull Open. 2024; 3(1):sgac024.

PMID: 39144775 PMC: 11205988. DOI: 10.1093/schizbullopen/sgac024.


References
1.
Kraguljac N, White D, Hadley J, Reid M, Lahti A . Hippocampal-parietal dysconnectivity and glutamate abnormalities in unmedicated patients with schizophrenia. Hippocampus. 2014; 24(12):1524-32. PMC: 7891897. DOI: 10.1002/hipo.22332. View

2.
Nucifora L, Tanaka T, Hayes L, Kim M, Lee B, Matsuda T . Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry. Transl Psychiatry. 2017; 7(8):e1215. PMC: 5611744. DOI: 10.1038/tp.2017.178. View

3.
Smeyne M, Smeyne R . Glutathione metabolism and Parkinson's disease. Free Radic Biol Med. 2013; 62:13-25. PMC: 3736736. DOI: 10.1016/j.freeradbiomed.2013.05.001. View

4.
Shimizu H, Kiyohara Y, Kato I, Kitazono T, Tanizaki Y, Kubo M . Relationship between plasma glutathione levels and cardiovascular disease in a defined population: the Hisayama study. Stroke. 2004; 35(9):2072-7. DOI: 10.1161/01.STR.0000138022.86509.2d. View

5.
Isgren A, Sellgren C, Ekman C, Holmen-Larsson J, Blennow K, Zetterberg H . Markers of neuroinflammation and neuronal injury in bipolar disorder: Relation to prospective clinical outcomes. Brain Behav Immun. 2017; 65:195-201. DOI: 10.1016/j.bbi.2017.05.002. View